within Pharmacolibrary.Drugs.ATC.A;

model A04AA02_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 0.38 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,
    adminCount     = 1,
    Vd             = 0.0031,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02333333333333333,
    Tlag           = 1200
  );

  annotation(Documentation(
    info ="<html><body><p>Granisetron is a selective 5-HT3 receptor antagonist used primarily as an antiemetic to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, and, to a lesser extent, postoperatively. It is an FDA-approved drug and is used clinically worldwide.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for healthy adult volunteers after oral administration of single 2 mg dose (film-coated tablet).</p><h4>References</h4><ol><li><p>Chen, R, et al., &amp; Hu, P (2019). Pharmacokinetics and safety of transdermal and oral granisetron in healthy Chinese subjects: An open-label, randomized, crossover study . <i>International journal of clinical pharmacology and therapeutics</i> 57(1) 24–31. DOI:<a href=&quot;https://doi.org/10.5414/CP203327&quot;>10.5414/CP203327</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30336808/&quot;>https://pubmed.ncbi.nlm.nih.gov/30336808</a></p></li><li><p>Doggrell, SA (2017). Granisetron in the treatment of chemotherapy-induced nausea and vomiting (CINV) - is there still a role after comparison with palonosetron?. <i>Expert opinion on pharmacotherapy</i> 18(10) 1019–1026. DOI:<a href=&quot;https://doi.org/10.1080/14656566.2017.1342809&quot;>10.1080/14656566.2017.1342809</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28612633/&quot;>https://pubmed.ncbi.nlm.nih.gov/28612633</a></p></li><li><p>Blum, RA, et al., &amp; Greenberg, HE (2003). Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. <i>Clinical therapeutics</i> 25(5) 1407–1419. DOI:<a href=&quot;https://doi.org/10.1016/s0149-2918(03)80128-5&quot;>10.1016/s0149-2918(03)80128-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12867217/&quot;>https://pubmed.ncbi.nlm.nih.gov/12867217</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A04AA02_1;
